Revance Therapeutics RVNC reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:10 PM.
Here's what investors need to know about the announcement.
Earnings
Revance Therapeutics beat estimated earnings by 38.89%, reporting an EPS of $-0.55 versus an estimate of $-0.9.
Revenue was up $27.76 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.03 which was followed by a 8.05% drop in the share price the next day.
Here's a look at Revance Therapeutics's past performance:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.77 | -0.70 | -0.95 | -0.89 |
| EPS Actual | -0.80 | -0.74 | -1.82 | -1.17 |
| Revenue Estimate | 59.35M | 46.10M | 46.55M | 27.94M |
| Revenue Actual | 58.13M | 49.33M | 49.92M | 29.02M |
To track all earnings releases for Revance Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
